Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K.

Slides:

Advertisements

Similar presentations

Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response Helle Krogh Johansen, Kasper.

Advertisements

The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa.

Rapid emergence of a ceftazidime-resistant Burkholderia multivorans strain in a Cystic Fibrosis patient Joshua R. Stokell, Raad Z. Gharaibeh, Todd R.

Christopher C. Miller, Christopher A

Prevalence and impact on FEV1 decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with Cystic Fibrosis E.

Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response Helle Krogh Johansen, Kasper.

Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment Winnie Ridderberg, Karen E.M.

Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients Helle Krogh Johansen, Samuel.

Is infection with hypermutable Pseudomonas aeruginosa clinically significant? Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir

William G. Flight, Jonathan Shaw, Susan Johnson, A

Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Lack of evidence of increased risk of bacterial transmission during cystic fibrosis educational programmes Winnie Ridderberg, Camilla Andersen, Michael.

Transmission of Pseudomonas aeruginosa in children with cystic fibrosis attending summer camps in The Netherlands R.W. Brimicombe, L. Dijkshoorn, T.J.K.

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of.

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

The ease of breathing test tracks clinical changes in cystic fibrosis

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis Malin Carlsson, Leif Eriksson, Tania Pressler, Ragnhild Kornfält,

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF Christina Schjellerup Dalbøge, Tacjana.

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

Vitamin A and lung function in CF

Distribution of the species of Achromobacter in a French Cystic Fibrosis Centre and multilocus sequence typing analysis reveal the predominance of A.

P. aeruginosa in the paranasal sinuses and transplanted lungs have similar adaptive mutations as isolates from chronically infected CF lungs Oana Ciofu,

Pulmonary nocardiosis in cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates G.A. Tramper-Stranders,

M. C. Alanin, K. G. Nielsen, C. von Buchwald, M. Skov, K. Aanaes, N

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden Per Kristian Knudsen, Hanne.

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Physiologic endpoints for clinical studies for cystic fibrosis

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Valerie Waters, Eshetu G

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis M. Wang, W. Ridderberg, C.R. Hansen, N. Høiby,

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients Valerie Waters, Eshetu G. Atenafu, Annie.

Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment Matthias Kappler,

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Voriconazole therapy in children with cystic fibrosis

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Cystic fibrosis and pregnancy in the modern era: A case control study

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K. Johansen, M. Skov Journal of Cystic Fibrosis Volume 12, Issue 6, Pages 609-615 (December 2013) DOI: 10.1016/j.jcf.2013.05.004 Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Case 1, lung function, microbiology and treatment from 2006 until January 2013. FEV1 and FVC are shown as % of predicted. Top bars show period of possible transmission (open) and period of antibiotic treatment (gray, shown as ceftazidime inhalation). Lightning shows first isolation of A. ruhlandii (Danish Epidemic Strain). Five-pointed star shows FESS. Open circles show intermittent colonization with P. aeruginosa. At the bottom, level of specific, precipitating anti-A. species antibodies is shown at different time-points. Journal of Cystic Fibrosis 2013 12, 609-615DOI: (10.1016/j.jcf.2013.05.004) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Case 2, lung function, microbiology and treatment from 2009 until January 2013. FEV1 and FVC are shown as % of predicted. Top bars show period of possible transmission and period of antibiotic treatment (shown as ceftazidime inhalation). Lightning shows first isolation of A. ruhlandii (Danish Epidemic Strain). Five-pointed star shows sinus-surgery. At the bottom, level of specific, precipitating anti-A. species antibodies is shown at different time-points. Journal of Cystic Fibrosis 2013 12, 609-615DOI: (10.1016/j.jcf.2013.05.004) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Multilocus sequence analysis showing the 4 isolates from the cases and the chronically infected patients. These 4 isolates cluster with the Danish epidemic strain of A. ruhlandii, strain A83. Journal of Cystic Fibrosis 2013 12, 609-615DOI: (10.1016/j.jcf.2013.05.004) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions